EWAF
TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
04/02/2025
Back to search
Official data from USPTO
GENZADA PHARMACEUTICALS
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
27
Latest update
04/09/2025
Trademark type
Combined
Nice classes
42
Filing date
11/30/2017
Registration date
07/24/2018
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
01/22/2024
Last transaction
04/09/2025
Responsible office
United States Patent and Trademark Office
Status code
702
Official register
Principal Register
First use anywhere
2015-05-00
First use in commerce
2015-05-00
Drawing code
3
Owner type
77
Owner location
DUBLIN 2, IE
Examiner
RICHARDS, SUSAN
Law office
L30
Current location
TMEG LAW OFFICE 103
Mark description
The mark consists of the stacked words "GENZADA" and "PHARMACEUTICALS", to the right of and partially underneath the stylized image of a tree.
Holders and representatives
Holders
ANKH LIFE SCIENCES LIMITED
Genzada Pharmaceuticals USA, Inc.
Representatives
C. Blair Barbieri HOVEY WILLIAMS LLP
Technical classification
Nice Classes
Class 42
Vienna Codes
No Vienna codes available.
Goods and services
Class 42
Pharmaceutical research and development; Scientific research and development
Publications
History of USPTO decisions and trademark events.
27 publications found
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
04/02/2025
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
04/02/2025
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
04/02/2025
NA85
NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED
01/22/2024
C15A
REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.
01/22/2024
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
01/22/2024
E815
TEAS SECTION 8 & 15 RECEIVED
07/27/2023
REM1
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
07/24/2023
R.PR
REGISTERED-PRINCIPAL REGISTER
07/24/2018
ASGN
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
06/13/2018
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
05/08/2018
PUBO
PUBLISHED FOR OPPOSITION
05/08/2018
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
04/18/2018
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
03/30/2018
XAEC
EXAMINER'S AMENDMENT ENTERED
03/19/2018
ALIE
ASSIGNED TO LIE
03/18/2018
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
03/18/2018
GNEA
EXAMINERS AMENDMENT E-MAILED
03/18/2018
CNEA
EXAMINERS AMENDMENT -WRITTEN
03/18/2018
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
03/17/2018
GNRT
NON-FINAL ACTION E-MAILED
03/17/2018
CNRT
NON-FINAL ACTION WRITTEN
03/17/2018
DOCK
ASSIGNED TO EXAMINER
03/13/2018
MDSC
NOTICE OF DESIGN SEARCH CODE E-MAILED
12/12/2017
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
12/11/2017
NWAP
NEW APPLICATION ENTERED
12/04/2017
Continuous trademark protection
Get notified about every new filing that threatens GENZADA PHARMACEUTICALS or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.